What does AnaptysBio, Inc. do?
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and…
What is AnaptysBio, Inc.'s P/E and P/B ratio?
AnaptysBio, Inc. has a P/E ratio of -50.1 and a P/B ratio of 112.81.
What is AnaptysBio, Inc.'s debt-to-equity ratio?
AnaptysBio, Inc. has a debt-to-equity ratio of 25.47.
How much does AnaptysBio, Inc. owe compared with what it owns?
AnaptysBio, Inc. owes $0.96 for every $1 it owns (balance sheet Mar 2026), which is high.
What is AnaptysBio, Inc.'s Positivity rank?
AnaptysBio, Inc. is ranked #6,710 of 6,774 companies globally and #3,941 of 4,000 in United States on PositoAI, with a Positivity Score of -61,022.
Does AnaptysBio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for AnaptysBio, Inc..
Where can I read the latest news about AnaptysBio, Inc.?
Recent headlines about AnaptysBio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does AnaptysBio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of AnaptysBio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.